Skip to main content
OpenTrials
Completed

NCT Number: NCT00424905

DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect

To assess the effects of Bacillus clausii (Enterogermina®) on fecal microbial flora (using Polymerase Chain Reaction - Denaturing Gradient Gel Electrophoresis - PCR-DGGE - Method) in antibiotic-treated children with complicated acute otitis media or beta-hemolytic streptococcal pharyngo-tonsillitis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–5 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sanofi-Aventis

Milan, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with persistency of symptoms and requiring antibiotics for bacterial upper respiratory tract infections, i.e. complicated acute otitis media (diagnosed by otoscopic examination) or beta-haemolytic streptococcal pharyngo-tonsillitis (diagnosed by pharyngeal swab and rapid antigen detection test or positive culture);
  • Outpatients or patients attending an emergency room for both diagnoses, and inpatients in case of complicated acute otitis media;
  • Written informed consent from both parents.

Exclusion criteria

  • History of clinically significant chronic diseases, or chronic diseases necessitating the use of continuous drug therapies, or of any disease that may interfere with the successful completion or the objectives of the trial;
  • Clinical evidence of relevant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological or of any disease that may interfere with the successful completion or the objectives of the trial;
  • Use of antibiotics, prebiotics or probiotics (medications or dietetic supplements) in the last 2 weeks prior to study entry;
  • Hypersensitivity to the investigational product;
  • Subjects enrolled in another trial in the previous three months.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Bacillus clausii

Drug

2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.

Primary outcomes

  1. Changes of microbial composition of fecal bacterial flora by PCR-DGGE analysis.

    Time frame: between samples obtained at baseline and follow-up

Secondary outcomes

  1. Changes from baseline of body weight

    Time frame: During the total study period

  2. Assessment of abdominal symptoms

    Time frame: Daily

  3. Presence of Bacillus clausii spores in feces

    Time frame: after heat shock treatment on selective medium.

  4. Number and rate of patients with GI symptoms and time to first development of symptoms.

    Time frame: recorded in a daily diary card for the total study period

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study.

Important dates

Study start
2006
Primary completion
2007
First posted
Jan 22, 2007
Registry last updated
Dec 1, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.